Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | Belinostat + Volasertib |
| Synonyms | |
| Therapy Description | |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| Belinostat | Beleodaq | PDX101|NSC726630|PX-105684 | HDAC Inhibitor 45 | Beleodaq (belinostat) is an HDAC inhibitor, which promotes tumor cell apoptosis, potentially leading to decreased tumor growth (PMID: 12939461, PMID: 16928830, PMID: 17935615). Beleodaq (belinostat) is FDA approved for patients with relapsed or refractory peripheral T-cell lymphoma (FDA.gov). |
| Volasertib | BI 6727|BI6727|BI-6727 | PLK1 Inhibitor 18 | Volasertib (BI 6727) inhibits polo-like kinase I (PLK1), resulting in cell cycle arrest and apoptosis in tumor cells (PMID: 27330107, PMID: 30782614, PMID: 32728610). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT02875002 | Phase I | Belinostat + Volasertib | Study of Volasertib and Belinostat in Patients With Relapsed and Refractory Aggressive B-cell and T-cell Lymphomas | Withdrawn | USA | 0 |